Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 1 · 33.3%High 0 · 0%

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Hand‐foot syndrome (grade ≥ 3) · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings 1: PLD with chemotherapy changes hand‐foot syndrome (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 4.01 [1, 16.01]
2 studies · 1028 participants
Very low

Summary of findings 1: PLD with chemotherapy vs PLD alone

Hand‐foot syndrome (grade ≥ 3) · recurrent platinum‐resistant EOC

Summary of findings 3: PLD with chemotherapy probably leads to lower hand‐foot syndrome (grade ≥ 3) compared with PLD alone (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 0.24 [0.14, 0.4]
2 studies · 785 participants
Moderate

Summary of findings 2: PLD alone vs other conventional chemotherapy

Hand‐foot syndrome (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes hand‐foot syndrome (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 2184 participants
Very low